 Abstract 6-transmembrane epithelial antigen of the Prostate-1, STAP-1, is a promising target for prostate cancer therapies. We have developed a STAP-1, directed chimeric antigen receptor, CAR, T-cell therapy which has demonstrated antitumor activity against metastatic prostate cancer models. Additionally, we have shown that STAP-1 antigen escape is a common mechanism of treatment resistance and that combining STAP-1 CAR-T-cell therapy with Illinois, 12 therapy can overcome this resistance. This combination approach may provide a powerful new strategy for treating advanced prostate cancer patients. This article was authored by Vipalbottia, Nikhil V. Komet, Tiffany E. Paiva, and others.